We are excited to announce that Ed Mascioli, M.D. has joined Matrivax as Chief Executive Officer (CEO) and Member of the Board of Directors. Dr. Mascioli is an experienced pharmaceutical and venture executive, and has held senior executive positions at Pfizer, Dapis Capital, Peptimmune, MPM Capital, Karos and Affinium. His leadership and business development expertise will be key in advancing our vaccine candidates through the clinic. Together, we look forward to developing our programs and building new partnerships. Welcome to the Matrivax team, Dr. Mascioli!
- Feb 27
- 1 min read
Please join us at World Vaccine Congress 2020, in Washington D.C.
April 6, 2020 at 10:00
WORKSHOP D (MORNING ONLY): TACKLE C. difficile
The Centers for Disease Control (CDC) has named C. difficile infections an urgent public health threat and the leading hospital-acquired infection in the U.S. With an enormous human toll, and significant health care costs, there is a clear need to prevent and treat this infection. Join us in this workshop as we hear from experts on their promising approaches to tackle the infection.
Workshop Leader: Kevin Killeen, Chief Scientific Officer, Matrivax
-Vaccine Effort Therapies
-Antibiotics: Merck’s DIFICID® (fidaxomicin)
-Fecal Microbiota Transplant
Kevin Killeen, Chief Scientific Officer, Matrivax R & D Corp
Mena Boules, Associate Medical Director, Medical Affairs, Gastroenterology, FERRING Pharmaceuticals
Pamela Sears, Vice President Clinical Science, Merck
Elizabeth Hohmann, Infectious Disease, Massachusetts General Hospital
- Nov 20, 2019
- 1 min read
At Matrivax, we are developing effective vaccines to address three of these concerning threats:
Urgent threat – C. difficile
Serious threat – S. pneumoniae, drug resistant
Serious threat – S. Typhi, drug resistant